OBJECTIVES: The rarity of familial neuroblastoma (NB) has allowed only a few linkage studies, most of which did not show any evidence of linkage to regions involved in somatic alterations or to genes implicated in other neurocristopathies seldom associated with NB. We screened a highly informative family with recurrent NB by genome-wide linkage analysis aimed at identifying chromosomal regions for NB predisposing genes. METHODS: A genome-wide screen was performed using 382 microsatellite markers. Multipoint model-based linkage analysis was carried out under a dominant mode of inheritance for the disease using the 'affected only' approach. RESULTS: Our analysis identified two haplotypes co-segregating with the disease on chromosomes 2p and 12p, and yielded maximum lod-score values of 3.01 (p < 0.0001) for markers on both intervals. CONCLUSIONS: Evidence of linkage was reported at 16p in North American families, whereas our studies excluded this interval and indicated other loci for disease predisposition, thus confirming the remarkable genetic heterogeneity of NB. These results suggest an oligogenic inheritance in NB involving more loci in genetic determination of the disease.
OBJECTIVES: The rarity of familial neuroblastoma (NB) has allowed only a few linkage studies, most of which did not show any evidence of linkage to regions involved in somatic alterations or to genes implicated in other neurocristopathies seldom associated with NB. We screened a highly informative family with recurrent NB by genome-wide linkage analysis aimed at identifying chromosomal regions for NB predisposing genes. METHODS: A genome-wide screen was performed using 382 microsatellite markers. Multipoint model-based linkage analysis was carried out under a dominant mode of inheritance for the disease using the 'affected only' approach. RESULTS: Our analysis identified two haplotypes co-segregating with the disease on chromosomes 2p and 12p, and yielded maximum lod-score values of 3.01 (p < 0.0001) for markers on both intervals. CONCLUSIONS: Evidence of linkage was reported at 16p in North American families, whereas our studies excluded this interval and indicated other loci for disease predisposition, thus confirming the remarkable genetic heterogeneity of NB. These results suggest an oligogenic inheritance in NB involving more loci in genetic determination of the disease.
Authors: Michael J Kelner; Mitchell B Diccianni; Alice L Yu; Mary R Rutherford; Leita A Estes; Ralf Morgenstern Journal: Free Radic Biol Med Date: 2014-01-29 Impact factor: 7.376
Authors: John M Maris; Yael P Mosse; Jonathan P Bradfield; Cuiping Hou; Stefano Monni; Richard H Scott; Shahab Asgharzadeh; Edward F Attiyeh; Sharon J Diskin; Marci Laudenslager; Cynthia Winter; Kristina A Cole; Joseph T Glessner; Cecilia Kim; Edward C Frackelton; Tracy Casalunovo; Andrew W Eckert; Mario Capasso; Eric F Rappaport; Carmel McConville; Wendy B London; Robert C Seeger; Nazneen Rahman; Marcella Devoto; Struan F A Grant; Hongzhe Li; Hakon Hakonarson Journal: N Engl J Med Date: 2008-05-07 Impact factor: 91.245
Authors: Yaël P Mossé; Marci Laudenslager; Luca Longo; Kristina A Cole; Andrew Wood; Edward F Attiyeh; Michael J Laquaglia; Rachel Sennett; Jill E Lynch; Patrizia Perri; Geneviève Laureys; Frank Speleman; Cecilia Kim; Cuiping Hou; Hakon Hakonarson; Ali Torkamani; Nicholas J Schork; Garrett M Brodeur; Gian P Tonini; Eric Rappaport; Marcella Devoto; John M Maris Journal: Nature Date: 2008-08-24 Impact factor: 49.962
Authors: Junne Kamihara; Franck Bourdeaut; William D Foulkes; Jan J Molenaar; Yaël P Mossé; Akira Nakagawara; Andreu Parareda; Sarah R Scollon; Kami Wolfe Schneider; Alison H Skalet; Lisa J States; Michael F Walsh; Lisa R Diller; Garrett M Brodeur Journal: Clin Cancer Res Date: 2017-07-01 Impact factor: 12.531
Authors: Nadine Van Roy; Katleen De Preter; Jasmien Hoebeeck; Tom Van Maerken; Filip Pattyn; Pieter Mestdagh; Joëlle Vermeulen; Jo Vandesompele; Frank Speleman Journal: Genome Med Date: 2009-07-27 Impact factor: 11.117
Authors: Marilena De Mariano; Roberta Gallesio; Marco Chierici; Cesare Furlanello; Massimo Conte; Alberto Garaventa; Michela Croce; Silvano Ferrini; Gian Paolo Tonini; Luca Longo Journal: Oncotarget Date: 2015-09-22